Story

Hims & Hers to Launch Peptides, But Wall Street Tempers Near-Term Revenue Hopes

ENTHMSVIIDZHZH-TWJAKOHI
Aug 12, 20262 min read
Hims & Hers to Launch Peptides, But Wall Street Tempers Near-Term Revenue Hopes
Text size
Background

Hims & Hers Health is set to enter the popular peptide treatment market, but Wall Street analysts and investors are cautioning that the new venture is unlikely to be a significant revenue driver this year. The telehealth firm's strategy hinges on a phased rollout that starts with currently legal products while awaiting key regulatory decisions on a wider range of treatments.

A Phased Market Entry

CEO Andrew Dudum confirmed to investors that Hims & Hers will begin selling several legally available peptides by the end of the year. The initial product line will include treatments such as NAD+, sermorelin, and glutathione, which are used for metabolic function, weight loss, and immune support, respectively.

This move taps into a market that analysts estimate could be worth between $2.2 billion and $3.3 billion. Peptides, which are short chains of amino acids, have gained notoriety for uses ranging from anti-aging to muscle recovery, though many operate in a regulatory gray area without formal FDA approval.

Cautious Near-Term Outlook

Analysts remain skeptical about the immediate financial impact of Hims' initial peptide offerings. Because treatments like NAD+ are already available, they do not carry the same pent-up demand as other peptides awaiting potential rescheduling by the U.S. Food and Drug Administration (FDA).

Sample IUX Markets – In-articleAd

"There’s no ‘release the floodgates’ demand like there is for other peptides that are in process of being rescheduled," said Paul Cerro, chief investment officer at Cedar Grove Capital Management, in a comment to Reuters. This contrasts with the rapid growth Hims experienced from selling GLP-1 weight-loss drugs. Morningstar analyst Keonhee Kim added that the prevalence of an unauthorized market for peptides makes it difficult to accurately assess the value of Hims' initial launch.

Long-Term Potential Hinges on FDA

The larger opportunity for Hims lies with peptides currently under FDA review, such as BPC-157, a compound used for tissue repair. The company has already begun testing for BPC-157 but is awaiting "full and final rulemaking" from the agency before a potential launch, according to Dudum.

While an FDA advisory panel recently backed allowing compounding of six peptides, the recommendation is non-binding, and experts believe a final decision could take about a year. Despite the wait, some see a significant long-term prize. Raul Shah, chief investment officer at DocShah Financial, told Reuters he expects Hims’ peptide business could generate over $1 billion in revenue within the next five to 10 years.

Hims holds a strategic advantage through its ownership of a major U.S. compounding pharmacy, which gives it in-house manufacturing capabilities. "Scaling new specialties is one of our core levers," Chief Financial Officer Yemi Okupe told Reuters, highlighting the company's experience in expanding its offerings.

Read next

More on Stocks
Back to latest news

LATEST